Abeona Therapeutics, Inc.

( )
ABEO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
LLYEli Lilly & Co. -0.72%363.001.1%$1183.94m
JNJJohnson & Johnson -0.13%176.990.7%$1095.82m
MRKMerck & Co., Inc. 0.04%107.500.7%$995.24m
PFEPfizer Inc. -0.10%49.150.9%$980.13m
ABBVAbbVie, Inc. -0.25%159.211.9%$904.50m
BMYBristol-Myers Squibb Co. -0.16%79.141.1%$749.90m
AZNAstraZeneca Plc 0.38%66.421.0%$361.53m
IDXXIDEXX Laboratories, Inc. 0.00%411.363.9%$222.64m
GSKGSK Plc -0.09%33.960.3%$201.84m
HZNPHorizon Therapeutics Plc 0.00%78.285.4%$201.37m
NVSNovartis AG -0.03%87.760.2%$189.98m
CTLTCatalent, Inc. 0.05%41.411.9%$163.88m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%212.728.0%$159.13m
NVONovo Nordisk A/S 1.11%120.160.1%$157.35m
SNYSanofi 1.08%45.880.2%$123.05m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.